Viewing nowViatin 50 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

MFDS item code 202100172 · Approved 2021.01.08 · Insurance code 644309620
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist blood sugar control in patients with type 2 diabetes, supplementing diet and exercise therapy. It can be administered alone when treatment is initiated and may be combined with metformin in cases where blood sugar control is insufficient with monotherapy. Additionally, it enhances blood sugar control when used in conjunction with other antidiabetic medications such as sulfonylureas, metformin, thiazolidinediones, and insulin. If multiple-agent therapy is still insufficiently effective, this drug can be added to enhance efficacy. By systematically managing blood sugar through gradual monotherapy or combination therapy, it helps maintain blood glucose levels.
This medicine is administered once daily at a dose of 100 mg when used as monotherapy or in combination therapy, with a maximum daily dose of 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (refer to Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically during treatment. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.
This medication can cause serious allergic reactions in some individuals. Such reactions may include anaphylaxis, angioedema, and severe skin conditions. Symptoms may appear within three months after taking the drug, so if these symptoms are suspected, discontinue the medication immediately and consult a physician. This medication may also cause a serious side effect known as acute pancreatitis, so it is important to carefully monitor for symptoms of pancreatitis. If pancreatitis is suspected, discontinue the drug immediately and seek medical attention. This medication should not be used in patients with type 1 diabetes or in those with diabetic ketoacidosis. Patients with a known severe allergy to this medication or its components should not use it. Patients with impaired kidney function may require a dose adjustment, and it is important to regularly monitor kidney function. Caution is especially needed when using this medication in conjunction with insulin or sulfonylureas, as there is a risk of hypoglycemia. Immediate action should be taken if symptoms of hypoglycemia occur, and adjusting the dose of other medications may be necessary. This medication may cause rare side effects, such as severe arthralgia or blistering disorders like pemphigoid, so if these symptoms occur, it is important to inform a physician immediately. Use of this medication is not recommended during pregnancy or lactation, and safety and efficacy have not been established in children and adolescents under 18 years of age. Elderly patients may have decreased kidney function, so dose adjustment and kidney function testing are necessary. In case of overdose, general treatment may be accompanied by consideration of hemodialysis if necessary. It is important to consult healthcare professionals if abnormal symptoms occur while taking this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air exposure, ideally at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's efficacy for a longer period.
Orange, biconvex, round film-coated tablet
30 tablets (10 tablets/PTP X 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.